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Melanoma has emerged as a paradigm of a highly aggressive and plastic cancer, capa-
ble to co-opt the tumor stroma in order to adapt to the hostile microenvironment, sup-
press immunosurveillance mechanisms, and disseminate. In particular, oncogene- and 
aneuploidy-driven dysregulations of proteostasis in melanoma cells impose a rewiring of 
central proteostatic processes, such as the heat shock and unfolded protein responses, 
autophagy, and the endo-lysosomal system, to avoid proteotoxicity. Research over the 
past decade has indicated that alterations in key nodes of these proteostasis pathways 
act in conjunction with crucial oncogenic drivers to increase intrinsic adaptations of mel-
anoma cells against proteotoxic stress, modulate the high metabolic demand of these 
cancer cells and the interface with other stromal cells, through the heightened release of 
soluble factors or exosomes. Here, we overview and discuss how key proteostasis path-
ways and vesicular trafficking mechanisms are turned into vital conduits of melanoma 
progression, by supporting cancer cell’s adaptation to the microenvironment, limiting or 
modulating the ability to respond to therapy and fueling melanoma dissemination.
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MeLANOMA
Cutaneous malignant melanoma (or simply melanoma) is a skin 
cancer that arises from the malignant transformation of melano-
cytes, the essential pigment (melanin)-secreting cells of the skin, 
whose incidence is quickly rising worldwide, and in particular 
in the developed countries (1). In the last decade, melanoma has 
emerged as a paradigm of aggressive cancer, typified by a high 
heterogeneity and poor therapeutic response. In fact, unless 
diagnosed at an early stage and surgically resected, melanoma 
evolves rapidly as a metastatic disease, highly resistant to therapy 
and associated with poor prognosis. Moreover, despite efforts for 
early detection and prevention, the median survival of patients 
with metastatic melanoma remains dismal (6–12 months) (2).
Crucial melanoma-associated oncogenic events have been 
identified, including a large variety of genetic and epigenetic 
defects in key components of the cell cycle, cell death, and 
epithelial-to-mesenchymal-like transition (EMT). Distinctive 
mechanisms related to the aggressive behavior of melanoma 
cells are the constitutive activation of growth factor receptors, 
such as c-Kit, PDGFR-α, EGFR, and the RAS/RAF/MEK/ERK 
pathway (or just MAPK pathway) (3, 4). It is known that 40–60% 
of all melanoma patients harbor a somatic mutation in the 600 
residues of BRAF, an early event in melanomagenesis, with 80% 
of these patients displaying V600E mutations, while 20% and a 
very small population of approximately 5–7% of patients harbor-
ing V600K or V600R mutations, respectively (5, 6). Moreover 
20, 2, and 1% of all melanomas are due to mutations in NRAS, 
KRAS, and HRAS, respectively, with the most common NRAS 
mutation occurring at position Q61 (7). Other known oncogenic 
mechanisms relate to the heightened activation of the PI3K/
protein kinase B (AKT) pathway (partially driven by the loss, 
mutation, or epigenetic silencing of the PTEN tumor suppres-
sor) (8–10), transcription factor NFκB, overexpression of the 
metabotropic glutamate receptor 1 (GRM1) (11), and dysregula-
tion (deletions, silencing, mutations) of genes involved in the 
cell cycle (CDKN2A/CDK4/CCND1) or regulating apoptosis, 
such as MDM2/4 and Apaf-1, and anti-apoptotic Bcl-2 family 
members, such as Bcl-xL and Mcl-1 [extensively reviewed in Ref. 
(12–15)]. Moreover, p53 has been recently shown to be a bona 
fide ultraviolet radiation (UVR) target gene in melanoma, and 
acquired, UVR-induced p53 mutations accelerate BRAFV600E-
driven melanomagenesis (16).
In addition to driving unrestrained proliferation and increas-
ing the resistance to apoptosis, these genetic and additional 
epigenetic alterations also modulate the cell autonomous ability 
of melanoma cells to invade and migrate (e.g., through altered 
expression of adhesion proteins). Moreover, both heightened 
NFκB signaling (17) and increased GRM1 expression (18), which 
foster glutamate-mediated MAPK-driven melanoma cell survival 
and the AKT–mTOR–HIF1 pathway (19), have been shown to 
support melanoma-associated proangiogenic signaling, thereby 
favoring melanoma growth and dissemination. Finally, the com-
plex gene expression landscape of melanoma is further regulated 
by several epigenetic mechanisms, including methylation, chro-
matin modification and remodeling, and through various classes 
of non-coding RNAs (20, 21).
Although melanoma can be considered a prototypical 
immunogenic tumor, it is a very aggressive cancer that can pro-
gress even in the presence of significant lymphoid infiltrate or 
demonstrated antitumor immune responses (22). This is largely 
due to the ability of melanoma to efficiently escape the immune 
system through various mechanisms [e.g., by the release of 
immune-silencing molecules such as vascular endothelial 
growth factor (VEGF), transforming growth factor (TGF)-β, 
interleukin (IL)-10, nitric oxide (NO), or prostaglandins], in 
part relying on the enhanced secretory activity of melanoma 
cells. Together, these observations suggest that deranged mela-
noma cell autonomous processes and melanoma cell–stromal 
cell interactions contribute to the establishment of a tumor-
promoting and immunosuppressive microenvironment driving 
melanoma growth.
Based on the accumulating knowledge on melanoma’s malig-
nant features, in recent years, different classes of novel drugs were 
approved for the treatment of advanced melanoma. However, tar-
geted molecular therapies relying on blockage of altered MAPK 
pathway, such as BRAFV600E (e.g., vemurafenib) and MAPK/
ERK kinase (MEK) (e.g., trametinib) inhibitors (23), have dem-
onstrated only partial antitumor responses in patients (24, 25). 
This is largely due to the rapid emergence of drug-resistant (6) and 
more aggressive melanoma clones (26), reflecting the high degree 
of cellular plasticity of melanoma cells and possibly pre-existing 
heterogeneity, which is one of the major hallmarks of this aggres-
sive disease. An important emerging class of anti-melanoma 
drugs targets co-inhibitory receptors limiting T cell-mediated 
antitumor responses through the agency of anti-CTLA-4 or 
anti-PD-1 or PD-L1 antibodies (27). However, despite the very 
promising objective clinical responses, it has become clear that 
a sizeable subset of melanoma patients does not respond equally 
well to immune checkpoint blockade strategies, which are often 
accompanied with severe toxic side effects (28). Thus, the limits 
and undesired side effects of current anti-melanoma therapeutics 
create a great interest to investigate new targets and develop novel 
approaches.
Recent data underscore that during melanoma progression 
certain housekeeping processes are used by melanoma cells to 
adapt and to sustain oncogene- and aneuploidy-driven dys-
regulations, much more than normal melanocytes would need 
them. In keeping with this, accumulating evidence indicate that, 
to support their intrinsic plasticity, melanoma cells rewind key 
homeostatic pathways, such as UPR, vesicle trafficking, and 
key lysosomal pathways, like autophagy. These pathways have 
been shown to be dynamically regulated throughout melanoma 
progression to increase intrinsic adaptations against proteotoxic 
stress, to accommodate the high metabolic demands of these 
cancer cells, and to modulate the interface with stromal cells 
within the tumor microenvironment. However, unlike other 
well-documented types of stress involved in malignant behav-
ior, such as genotoxic, oxidative, and metabolic stress in cancer 
cells, much less is known about the mechanisms regulating 
proteostatic stress and how perturbations in the proteome of 
cancer cells, and more specifically in melanoma, affect disease 
progression, despite its prominent manifestation in other human 
disorders (29).
FiguRe 1 | Deranged proteostasis network in melanoma supports the main hallmarks of cancer. A simplified overview of the main components of the 
proteostasis network is discussed in this review and its implications for melanoma biology. The deranged proteostasis network (PN) in the depicted melanoma cell; 
the inner-most circle (light gray) represents the general proteostasis control (GPC) triad (35) and includes the synthesis, degradation, posttranslational modification, 
and trafficking of proteins. The second circle (dark gray) shows the signaling pathways that influence the level and activity of the triad. The outer radial circle gives 
the summary of the key melanoma-associated processes, which have been shown to be affected/modified by alterations of the PN [adapted from Ref. (36)]. EMT, 
epithelial mesenchymal-like transition; HSR, heat shock response; UPR, unfolded protein response; ELS, endo-lysosomal system; ERAD, ER-associated 
degradation; MAPS, misfolded-associated protein secretion; PTMs, posttranslational modifications.
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In this review, after a brief introduction of the main pathways 
regulating proteostasis, we discuss in more molecular details 
altered mechanisms governing the proteome of melanoma cells 
and how they modulate melanoma survival, metastatic spread-
ing, and therapy responses.
THe PROTeOMe uNDeR CONTROL:  
A BRieF OveRview OF KeY PATHwAYS 
ReguLATiNg PROTeOSTASiS
The regulation of intracellular protein turnover (synthesis/
degradation), protein conformation/folding, protein–protein 
interactions, and localization (trafficking) are crucial processes 
preserving the quality of the proteome (proteostasis), which 
is required for a cell to function efficiently and to dynamically 
respond to internal and external cues. In line with their role in 
the maintenance of a healthy proteome, various proteostasis 
mechanisms have been shown to be disturbed during aging as 
well as in many pathological conditions, including cancer and 
neurodegeneration (30, 31). Proteostasis is fine-tuned by vital 
protein quality control mechanisms, including autophagy and 
the proteasomal and endo/lysosomal pathways, which make 
up the triad of modalities that encompass general proteostasis 
control (GPC, Figure 1). These modalities utilize various classes 
of chaperones, folding enzymes, posttranslational modifications, 
synthesis, trafficking and degradation mechanisms, which work 
in concert and are modulated by stress pathways, ultimately 
sensing changes in the integrity of the proteome. In the follow-
ing paragraphs, we will provide a simplified introduction on the 
main mechanisms contributing to proteostasis; a more detailed 
discussion is beyond the scope of this essay and can be found in 
excellent recent reviews (32–34).
To maintain proteostasis and prevent/minimize proteotoxic 
stress as a result of the accumulation of aged, aberrantly folded, 
or aggregated proteins, cells are heavily dependent on various 
quality control mechanisms. Cytoplasmic proteostasis is vitally 
regulated by the heat shock response (HSR), which is largely 
mediated by the stress-induced activation of heat shock tran-
scription factor 1 (HSF1). Upon cellular stress, the activation of 
HSF1, the master regulator of the HSR, causes the induction of 
the expression of HSPs, molecular chaperones that protect the 
proteome against misfolding and subsequent aggregation, by 
facilitating folding, transport, and degradation (32). HSPs exert 
BOx 1 | The unfolded protein response.
Loss of the ER folding capacity leads to the accumulation of unfolded or 
misfolded proteins and the initiation of the unfolded protein response (UPR). 
The UPR is sensed by the luminal domain of three ER-stress transmembrane 
proteins, which are PERK, IRE1 – the latter harboring both protein kinase and 
endoribonuclease activities –, and ATF6. Binding of GRP78 (also called BiP) to 
the luminal domain of these ER transmembrane proteins keeps them inactive. 
Upon loss of ER homeostasis, which causes an accumulation of unfolded 
proteins, GRP78 is titrated away from these ER-stress sensors to bind to 
the hydrophobic domains of misfolded proteins, allowing the dimerization/
oligomerization of PERK and IRE1α, and the migration of ATF6 to the Golgi, 
ultimately launching the UPR (33). Active PERK attenuates global protein syn-
thesis by the phosphorylation of eIF2α, thus relieving pressure on the stressed 
ER (39, 40), while at the same time allowing cap-independent translation of 
mRNA important in both pro-survival and pro-death stress response proteins 
(41). An essential role here is played by the activating transcription factor 4 
(ATF4), which stimulates the synthesis of essential ER chaperones, proteins 
involved in ER homeostasis (42) as well as autophagy (43). However, ATF4 
can also induce the expression of the pro-apoptotic transcription factor C/
EBP homologous protein CHOP, enabling the PERK branch of the UPR to 
elicit cell death under conditions of unresolved ER stress (44). The antioxi-
dant response element (ARE) transcription factor Nrf2 is also induced by 
PERK and is a homeostatic response to counter reactive oxygen species 
(ROS) (45). Negative feedback by kinase inhibition of PERK (46) and eIF2α 
dephosphorylation (47) as stress is resolved, restores the cell’s normal transla-
tional capacity. IRE1 displays protein kinase and endoribonuclease activities. 
Oligomerization and autophosphorylation of IRE1 results in RNase-domain 
activation leading to unconventional splicing of the XBP1 mRNA (48). XBP1 
splicing generates an active transcription factor that upon nuclear transloca-
tion induces the expression of several cytoprotective genes involved in ER 
quality control, such as ER-resident chaperones involved in protein folding 
and the tagging of terminally mutated proteins for ER-associated degradation.
(ERAD). IRE1 can also degrade specific mRNAs through a process termed 
regulated IRE1-dependent decay of mRNA (RIDD). As in the case of PERK, 
while XBP1splicing is mostly involved in evoking cytoprotective responses, 
IRE1 can engage cell death pathways as well. This can occur either through 
its scaffolding role at the ER leading to the activation JNK (49) and through 
RIDD-mediated degradation of pro-survival mRNAs, which increases with the 
intensity of ER stress (50). Following release from the ER, ATF6 translocates 
to the Golgi apparatus where it is cleaved by Golgi-resident proteases into an 
active transcription factor (51), which binds to promoters containing ER-stress 
response elements (ESRE) and regulates the expression of key enzymes and 
chaperones of the UPR machinery (52).
Although PERK, IRE1, and ATF6 each appear to play functionally separate 
roles in stress signaling, conserved overlap in chaperone induction and cell 
death activation exist, further highlighting the importance of cellular proteosta-
sis and how it is coupled to cell death pathways.
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their first line-quality control activity by assisting folding of 
de novo synthesized protein during their transit within cellular 
compartments, facilitating refolding of stress-denatured proteins, 
oligomeric assembly, protein transport, and providing assistance 
in proteolytic degradation. Moreover, HSPs assist in the preven-
tion of protein aggregation by shielding the exposed hydrophobic 
surfaces of partially unfolded proteins (34).
While HSR regulates cytoplasmic proteostasis, the unfolded 
protein response (UPR) is activated in response to changes in ER 
folding capacity and regulates ER proteostasis.
The transcriptional program that is put in motion by the activa-
tion of the UPR preferentially acts as an intermediate response to 
reestablish the ER protein folding and synthesis output as a con-
sequence of increased detection of unfolded or misfolded proteins 
in the ER lumen (33) (see Box 1 for molecular description of the 
UPR). During the initial phase, the UPR is an adaptive response 
that potentiates a diverse array of quality control mechanisms 
aiming to reestablish ER folding capacity and homeostasis. This is 
mainly achieved by temporarily shutting down protein synthesis, 
to reduce folding burden in the ER lumen, while increasing the 
expression of various chaperones and folding enzymes (33). 
Besides the UPR emanating from the ER (UPRER), recent stud-
ies have implicated another transcriptional, mitochondrial stress 
response, called the mitochondrial unfolded protein response or 
UPRmt, as major contributor of proteostasis. Although partially 
overlapping with elements of the HSR and UPRER and not entirely 
understood in mammalian cells, the UPRmt program is elicited to 
promote folding, limit import, and reduce translation of mitochon-
drial proteins and is selective for mitochondrial chaperones, such 
as the mitochondrial HSP60 (37). However, if stress persists and 
proteostasis is not reestablished, both UPR-signaling mechanisms 
activate mechanisms capable of inciting cell death. In the scenario 
of the best characterized UPRER, this involves increased expression 
of the transcription factors ATF4 and induction of CHOP, down-
stream in the PERK–eIF2α branch of the ER-stress response (38).
Both the HSR and UPR-signaling pathways work in conjunc-
tion with major proteolytic systems, such as the proteasome, 
autophagy, and the endo-/lysosomal system (ELS) (33, 53), to 
maintain the integrity of the proteome and attenuate proteo-
toxicity, thus establishing a complex network of interconnected 
proteostasis mechanisms.
Typically, under conditions of loss of ER proteostasis misfolded/
abnormally, folded proteins are re-translocated to the cytoplasm 
and subsequently degraded by the ubiquitin–proteasomal system 
(UPS) through a process called ERAD [reviewed in Ref. (43)]. 
Alternatively, ER protein overload can be alleviated by the secre-
tory pathway, through a newly described mechanism whereby 
unfolded glycosylphosphatidylinositol (GPI)-anchored proteins 
are exported via the Golgi apparatus to the plasma membrane 
(PM) for subsequent endocytosis and lysosome degradation (54).
In the cytosol, non-functional/damaged or misfolded proteins 
are sensed and chaperoned. Failure to refold the target proteins, 
induces the activity of E3 ubiquitin ligases, including the co-
chaperone carboxyl terminus of co-chaperone carboxyl terminus 
of heat-shock cognate 70 (HSC70)-interacting protein (CHIP), 
resulting in the ubiquitination of unfolded/damaged proteins 
and their targeting for degradation through the UPS (55). The 
ubiquitin-tag, is a well-known posttranslational modification 
allowing polypeptides to be targeted and delivered to the 26S 
proteasome for degradation (56–59). However, if the capacity of 
the chaperone-mediated refolding machinery and the UPS are 
overloaded, or if the misfolded proteins form large aggregates 
that are resistant to proteasomal degradation, these ubiquitin-
modified substrates are recognized and targeted to the lysosome 
through autophagy-mediated pathways. In line with this, in addi-
tion to the ERAD pathway, autophagy has been shown to play an 
important role in restoring ER proteostasis (60).
Protein ubiquitination has been moreover recognized to be a 
crucial signal for the selection and delivery of cytoplasmic cargo, 
not only restricted to aberrantly folded proteins and aggregates 
but also to damaged organelles (like the mitochondria), to the 
autophagy machinery. This mechanism confers specificity to 
BOx 2 | Autophagy pathways.
To date, three different mechanisms have been identified in mammalian 
cells, which facilitate the lysosomal degradation of intracellular compo-
nents: chaperone-mediated autophagy (CMA), macroautophagy, and 
microautophagy.
Macroautophagy is the major lysosomal degradation pathway 
hallmarked by formation of a double-membraned autophagosomes (48, 
49). Dysfunctional/obsolete organelles and proteins, both soluble and 
aggregates that are tagged for recycling, are encapsulated in the forming 
autophagosomes that ultimately fuse with the lysosome (autolysosomes) 
for degradation (66). At the molecular level, the induction of autophagy 
is regulated by two kinase complexes; the ULK1 complex that includes 
ATG13, FIP200, and ATG101, and is suppressed by mTOR and the large 
class III PI3P–Vps34 complex, which includes among others Beclin 1, which 
generates PI3P on the nascent autophagosome. These kinase complexes 
in turn coordinate the recruitment of downstream autophagic proteins, 
including WIPI1 and 2, the membrane associated ATG9, two ubiquitin-like 
protein complexes ATG12–ATG5–ATG16 and the LC3/GABARAP (ATG8) 
proteins which, upon phospatidylethanolamine (PE)-lipidation, become 
integrated in the autophagosomal membrane and become degraded upon 
fusion with the lysosome (62, 67, 68). Selective macroautophagy pathways 
can lead to the clearance of specific targets, such as protein aggregates 
(aggrephagy), organelles such as mitochondria (mitophagy), endoplasmic 
reticulum (reticulophagy), and peroxisomes (pexophagy), or lipid droplets 
(lipophagy), glycogen particles (glycophagy), and pathogens (xenophagy). 
In analogy to the proteasome, selective cargo recognition and autophagic 
degradation also involves ubiquitination. The autophagic degradation 
of protein aggregates requires the ubiquitin receptors p62/SQSTM1 and 
NBR1, which recognize polyubiquitinated targets and bridge them to the 
autophagy machinery. Both autophagic adapters are cargo receptors and 
autophagy substrates (69) and share similar domain architecture, interac-
ting with LC3/Atg8 through an LC3-interacting region (LIR) and binding 
to monoubiquitin and polyubiquitin via the C terminal ubiquitin-associated 
(UBA) domain.
Chaperone-mediated autophagy involves the selective degradation of 
soluble proteins exposing a KFERQ-related sequence, which are directly 
targeted to the lysosomes upon their recognition by the cytosolic heat 
shock cognate 70 (hsc70) (70). The substrate-chaperone complex interacts 
with the lysosome-associated membrane protein-2A (LAMP-2A) receptor, 
which ensures its translocation into the lysosome assisted by lysosomal 
hsc70. This process encompasses four main steps, which are as follows: (a) 
substrate recognition and targeting to the lysosomes; (b) substrate binding 
to the lysosomal receptor and unfolding; (c) substrate translocation through 
the lysosomal membrane; and (d) substrate degradation in the lysosomal 
lumen (71).
Microautophagy is the third subtype of autophagy, which to date has not 
yet been well characterized in mammalian cells (72). It involves the interna-
lization of cytosolic cargo through invagination of the lysosomal membrane, 
through a process that resembles the formation of multivesicular bodies 
(MVBs) (72). Although the molecular players have not been well defined and 
the relationship between this process and the formation of MVBs is elusive, 
microautophagy underlies the ability of the lysosomal membrane to direct 
engulf cytosolic components. During this phenomenon, a specialized “auto-
phagic tube” is formed by invagination of the lysosomal membrane, which 
encloses portions of the cytosol through an ATP-dependent process that is 
accompanied by drastic changes in the distribution of both lysosomal lipids 
and proteins. In mammalian cells, non-selective microautophagy clears solu-
ble intracellular substrates, whereas selective microautophagy mechanisms 
have only been described in yeasts.
While these autophagy pathways are constitutively active, macroauto-
phagy and CMA are stimulated in response to a variety of common metabolic 
and oxidative stressors, and mutual compensatory mechanisms exist to 
balance and compensate these degradation pathways (70). Microautophagy, 
is often stimulated in parallel with macroautophagy, especially in response to 
starvation or mTOR inhibition, and is thought to be a mechanism important to 
reestablish lysosomal membrane homeostasis and regulate lipid metabolism 
and endocytosis (73).
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the process of autophagy, which was initially thought to occur 
in an aspecific manner. Ubiquitinated cargo is recognized by the 
binding of shuttling factors or specific receptors, of which p62 
(also called sequestosome 1 or SQSTM1) and neighbor of BRCA1 
gene 1 (NBR1) are the prototypes, that tether it to the autophago-
somes, the hallmark of macroautophagy (thereafter called simply 
autophagy, see Box 2 for further description). During autophagy, 
damaged or aberrant cytoplasmic material is sequestered by 
double-membraned autophagosomes and trafficked to the lys-
osomes, where upon fusion, is ultimately degraded by lysosomal 
hydrolytic enzymes. However, autophagosomes can fuse with an 
associated membrane protein 1 (LAMP1)-positive compartment 
before acquiring lysosomal proteases and enter the endocytic 
pathway through fusion with late endosomes (LEs), forming the 
amphisomes and hybrid organelles (61). Although a complete 
description of the molecular pathways regulating autophagy is 
beyond the scope of this review [for further details, readers are 
referred to Ref. (62–64) and Box 2], it is important to note that 
the ER plays an instrumental role in the modulation of autophagy 
and is thought to provide an important membrane source during 
the early steps of autophagosome formation (65).
Additionally, proteostasis is regulated at different levels through 
the ELS (schematically described in Box 3), which interfaces and 
overlaps extensively with the autophagy machinery by sharing 
a number of tethering, fusion, and trafficking components (74).
At the level of the LEs/MVBs and lysosomes, proteostasis is 
performed by a variety of differing mechanisms, chiefly regulated 
by ubiquitin signals, including, protein sorting (recycling) and 
targeted clearance (degradation) of the cargo (87). Furthermore, 
LE/MVBs can fuse with the cell membrane to release proteolytic 
enzymes and signaling molecules or ILVs, called exosomes, 
thereby regulating intercellular communication (80).
A number of studies have further highlighted the close 
cross talk between autophagy and the UPS (88–91). Moreover, 
perturbed autophagy may also lead to the impaired degradation 
of specific UPS clients; such that reduced autophagic capacity 
can alter the efficiency of the proteasome through mechanism 
regulated by the key autophagic receptor p62 (55, 90, 91). This 
suggests that the autophagy and UPS proteolytic machineries are 
functionally linked and do not simply respond to compensatory 
mechanisms. Moreover, evidence coupling the proteasomal and 
endosomal machinery is also emerging (92, 93).
Recently, the autophagy machinery (94) and the UPS (94) have 
been shown to be implicated in unconventional secretion path-
ways, facilitating the extracellular delivery of cytosolic proteins 
directly from the cytosol, without transiting trough the classical 
ER-to-Golgi pathway. In case of the UPS-mediated pathway, it has 
been suggested that this unconventional secretory mechanism, 
called misfolded-associated protein secretion or misfolded-asso-
ciated protein secretion (MAPS) and involving the LE as delivery 
carriers, may help proteostasis through the export of misfolded 
proteins when the proteasomal degradation capacity in the cell is 
overwhelmed, a condition that may lead to the accumulation of 
detrimental protein aggregates (94).
In conclusion, although the molecular nature of all these 
interactions and the identity of the shared components have not 
been fully characterized, it is clear that there is a more significant 
BOx 3 | The endo-lysosomal system.
The endo-lysosomal system (ELS) is a dynamic, interconnected vesicular 
network including a set of intracellular membranous compartments, which 
comprise the endocytic pathway (early endosomes, recycling endosomes, 
late endosomes, and lysosomes) (75). Endocytosis is initiated by invagination 
of a portion of the plasma membrane, typically through the action of chlatrin-
coated pits, or through plasma membrane caveolae, or through larger vesicles 
like micropinosomes. Upon internalization, endocytic vesicles fuse with the 
mildly acidic early endosomes, to be finally transported to the acidic com-
partments, namely the late endosomes (LEs) and finally the lysosomes for 
degradation. In the ELS, the maturation of endosomes into LEs/lysosomes 
entails a significant shift in the acidity of the vesicles, a process that ultimately 
regulates vesicle trafficking, protein sorting, and targeted degradation of 
sorted cargo. These vesicular pathways involve various membrane fusion 
events that are vitally regulated by members of the Rab small GTPase family, 
tethering complexes, and actual membrane fusion events guided by SNARE 
proteins (51) and posttranslational modifications, primarily ubiquitinilation. The 
early endosomes are regulated predominantly by the small GTPase Rab5 (52) 
and act as the major sorting station holding the capacity to go back to cell 
surface for reuse (recycled endosomes), a process under the regulation of Rab 
4 and 11 (76, 77), or mature into late endosomes (LEs), which is facilitated by 
the transition from Rab5 to Rab7. The major roles of LEs are the biogenesis 
of intraluminal vesicles and sorting of ubiquitinated membrane proteins for 
lysosomal degradation (78). An LE demonstrating intraluminal vesicle (ILVs) 
formation, in a process of inward membrane invagination involving the ESCRT 
complexes, is referred to as a multivesicular body (MVBs) (79). In the end, the 
MVBs/LEs fuse with lysosomes for degradation. However, MVBs can also 
fuse with the plasma membrane leading to the release of their internal vesicles 
into the extracellular space (exosomes) (80).
An intense cross talk exists between trafficking mechanisms and mole-
cular modulators of autophagosomes and ELS. For example, autolysosome 
formation and the trafficking of MVBs to lysosomes are processes regulated 
by LE-associated proteins, among which the small GTPase, Rab7A, a critical 
regulator of endosomal maturation/functionality (81–83) and syntaxin 5 (84). 
Moreover, endosomal membranes can contribute to the formation of autopha-
gosomes through vesicles derived from Rab11-positive recycling endosomes, 
where both ULK1 and mATG9 reside and sense autophagy induction (85). 
Additionally, mATG9 and ATG16L1-containing vesicles can traffic through the 
endocytic pathway via different routes and fuse with recycling endosomes 
(86). These examples clearly show that autophagosomes can undergo fusions 
with both acidic vesicles of the endo-lysosomal system as well as earlier 
compartments of the endocytic pathway.
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cross talk within the complex network of the pathways regulating 
cellular proteostasis and protein quality control, than originally 
hypothesized. This is perhaps not surprising considering that 
ubiquitin-regulated pathways, autophagosomes, endosomes, 
and lysosomes are emergently recognized as highly dynamic 
and cross-communicating signaling hubs controlling not only 
intracellular protein/organelle degradation but also the strength 
and duration of signaling pathways originating from intracellular 
and surface receptors/complexes as well as the composition of the 
surface proteome and secretome (95–98).
In the following sections, we will discuss how these major 
housekeeping pathways are recruited to support different features 
of melanoma plasticity and aggressiveness.
ADAPT AND SuRvive: ALTeRATiON OF 
CYTOPLASMiC AND uPR-BASeD 
PROTeOSTASiS iN MeLANOMA
Cancer cells are particularly exposed to a variety of intrin-
sic (oncogenic expression and aneuploidy) and extrinsic 
perturbations (hypoxia, glucose deprivation, acidosis) that alter 
global proteostasis, resulting in the accumulation of flawed or 
misfolded proteins. Moreover, to keep pace with their increased 
metabolic/energy request and heightened proliferation, cancer 
cells usually expand their protein folding and trafficking capaci-
ties. Indeed, oncogenic expression and chromosome imbalance, 
characteristic of malignant cells, impose pressure on proteostasis 
control and encumber cellular quality control mechanisms, 
mainly due to imbalances in protein synthesis, e.g., excessive/
overexpression of proteins that often culminate in protein aggre-
gation and the activation of degradation and/or export pathways. 
To cope with these cues, cancer cells tend not only to upregulate 
various mechanisms regulating proteostasis, by e.g., upregulating 
chaperones and expanding their secretory/vesicular pathways but 
also become heavily reliant on them – a phenomenon known as 
“non-oncogene addiction” (99).
In this context, melanoma represents a key paradigm. 
Accumulating evidence shows that melanoma cells display a 
significant increase in ER and cytoplasmic chaperones, driven by 
the UPR (Box 1), which act initially to increase protein folding 
efficiency, along with an elevated expression of many vesicular 
trafficking related genes, such as Rab7 (100), TBC1D16 (101), 
and Rab27 (102). Moreover, the relevant role that chaperones 
(for example; HSP70, HSP90) play in preserving melanoma 
survival and plasticity is emphasized by their correlation with 
disease progression (103, 104) and the manifested vulnerability 
that melanoma cells exhibit following perturbations of global 
proteostasis. A study comparing the expression levels of HSPs 
across patient clinical parameters showed that, with the notable 
exception of HSP32, whose expression correlated with improved 
patient survival, increased expression of HSP90 and HSP40 
correlated with advanced stages of melanoma, and in the case of 
HSP40 with decreased patient survival (105). In line with this, 
another study observed an indispensable role of HSF1 in mela-
noma progression and migration, thus highlighting its potential 
as therapeutic target in melanoma (106).
Increased chaperone expression may also allow for heightened 
protein synthesis, feeding melanomas proliferative capacity 
(107). Moreover, chaperones are multifaceted proteins that 
modulate signaling pathways as a consequence of their high 
affinity for unfolded or misfolded proteins, drawing them away 
from their regulatory role in signaling pathways. For example, 
HSP90 is an essential cytoplasmic chaperone, renowned for its 
protective capacity against a number of chemotherapeutics and 
implicated as a modulating factor of drug resistance (108). Over 
100 client proteins have been identified for HSP90, many of 
which are important in the progression of cancer (3, 4), includ-
ing MEK, AKT, Apaf-1, VEGFR, and c-MET (109). Moreover, 
the chaperone HSP90 stabilizes mutant BRAFV600E, further 
supporting the prognostic relevance of HSP90 upregulation in 
melanoma and the close correlation between oncogenic drivers 
and increased chaperone expression (108).
Interestingly, a recent study showed that upon cellular stress 
HSF1 physically interacts with and is directly phosphorylated 
by MEK, a pivotal kinase of the MAPK pathway, and as a conse-
quence promotes melanoma growth (110). Furthermore, MEK 
inhibition in these BRAFV600E mutant melanoma cells, caused 
HSF1 inactivation, protein destabilization, and aggregation that 
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lead to melanoma cell demise by excessive proteotoxic stress. 
Interestingly, MEK–HSF1 inhibition or proteasomal inhibition, 
also led to the accumulation of aggregation-prone proteins 
forming amyloid fibrils enriched in beta sheet structure, through 
the process of amyloidogenesis. Increased amyloidogenesis by 
MEK or HSF1 inhibition blunted melanoma growth, by exac-
erbating proteotoxic stress to a lethal threshold, thus suggesting 
that the induction of proteotoxic stress might have relevant 
anti-melanoma effects and represent a promising therapeutic 
strategy (110).
Unfortunately, the use of bortezomib, a clinically used 26S 
proteasome inhibitor, for the treatment of melanoma gave disap-
pointing results (111). One rationale for this was the tendency 
of bortezomib to upregulate ER stress, cytoprotective autophagy, 
and the detectable expression of key cytoprotective chaperones, 
such as HSP70, all of which are potential therapeutic targets in 
melanoma (112). In line with this, targeting HSP70 significantly 
increased the efficacy of bortezomib to incite cell death and 
reduced the metastatic potential of melanoma (112). In agree-
ment with this strategy, while single agent MEK inhibition or 
bortezomib were shown to be only partially beneficial, their 
combination markedly synergized their antitumor and anti-
metastatic potential in a xenografted model of melanoma (110).
Taken together, from a cell focused perspective, these observa-
tions suggest that targeting multiple nodes of the proteostasis net-
work of melanoma cells would significantly enhance melanoma 
cell’s vulnerability to proteotoxic stress.
Melanoma cells are moreover renowned for their chronic 
activation of the UPRER (107), and a significant proportion of 
research has committed to understanding the molecular and 
therapeutic potential of this adaptation [reviewed in Ref. (107)]. 
The importance of ER homeostasis in melanoma is highlighted by 
the constitutive upregulation of certain ER-resident chaperones, 
such as GRP78, and their correlation with upstream, disease 
initiating, NRAS, or BRAF oncogenic mutations (107). In fact, 
ample evidence indicates GRP78 as a prognostic marker of 
melanoma, where its increased expression correlates with disease 
progression (113). The observed enhancement in basal UPRER 
activation in melanoma cells is in part justified by the increased 
protein synthesis burden required for proliferation, driven by 
the constitutively activation of the MAPK pathway and AKT, 
downstream mediators of the RAS–RAF and PI3K pathways, 
respectively (107). However, while some studies have shown that 
inhibition of BRAF or MEK signaling in melanoma increases ER 
stress, yet conversely, others have demonstrated that inhibition of 
oncogenic BRAF or MEK resulted in a marked reduction in IRE1 
and ATF6 based signaling (107) (Box 1). Interestingly however, 
the capacity of the RAS–RAF pathway to modulate PERK-based 
signaling was not altered (107).
Various HSP proteins, including HSP70, are also found at the 
cell surface and/or are secreted from melanoma cells under stress 
conditions eliciting loss of proteostasis. Increased expression of 
HSP70 in melanoma cells triggered its rerouting through the ELS, 
allowing excess HSP70 to be deposited to the cell surface and 
be released into the extracellular space (103). This suggests that 
stress conditions altering HSP expression in melanoma cells may 
concomitantly favor their extracellular release through the ELS.
However, the extracellular route of delivery, and especially 
the context in which chaperones are exposed or released, 
whether they originate from living or dying cells, modulate 
their known extracellular immunomodulatory activities. 
During immunogenic cancer cell death (ICD), a cancer 
cell death subroutine triggered by a limited set of assorted 
anticancer therapies resulting in the efficient stimulation 
antitumor immunity (114), vital homeostasis processes favor 
the trafficking and export of key chaperones to the surface of 
the dying cells, where they act as damage-associated molecular 
patterns (DAMPs). During ICD, loss of ER proteostasis and 
an intact secretory pathway were found to be required for the 
surface exposure of the ER luminal chaperone calreticulin 
(CRT), a major ICD-associated danger signal, whose exodus 
is often accompanied by the extracellular exposure or release 
of HSP70 (115). Notably, in melanoma cells dying in response 
to the genotoxic agent melphalan (Mel), the limited induction 
of an ER-stress response failed to elicit the surface emission 
of CRT and HSP70 (116) and to efficiently stimulate a CD8+ 
T cell-dependent antitumor response, in a prophylactic 
immunization mouse model (116). Intriguingly, the anticancer 
vaccination potential of Mel was potentiated by the exogenous 
addition of recombinant CRT (116). This concept is further 
highlighted by the observation that upon ROS-induced loss 
of ER proteostasis, autophagy counterbalances the mobiliza-
tion of CRT on the surface of dying melanoma cells (possibly 
by reducing ROS-mediated loss of ER proteostasis), thereby 
weakening the functional interaction between dying mela-
noma cells with antigen-presenting cells (117). Likewise, the 
heightened autophagic flux harbored by the BRAFV600E 
inhibitor-resistant melanoma cells, hindered the surface expo-
sure CRT and HSP90, in response to cell death induced by the 
blockade of the hyperactive MEK pathway (118).
Recently, melanoma cell-associated activation of the oncogenic 
Wnt/beta-catenin signal was found to prevent antitumor immu-
nity by inhibiting the intratumoural recruitment of dendritic cells 
and T cells (119). Interestingly, microphthalmia-associated tran-
scription factor (MITF), the crucial melanocytes lineage factor, 
has been recently shown to misregulate endolysosomal biogenesis 
and to promote Wnt signaling (120) (as discussed later in more 
details). Whether the melanoma cell-intrinsic and Wnt-mediated 
immunosuppressive mechanism described above is regulated by 
MITF-driven endolysosomal changes has not been investigated 
yet. However, considering the emerging pro-tumorigenic role of 
the heightened ELS in melanoma (discussed in further sections), 
this hypothesis needs urgent validation.
In conclusion, various proteostasis mechanisms leading to 
the upregulation of cytoplasmic chaperones or expansion of the 
ELS compartment are recruited by melanoma cells to support cell 
autonomous adaptation to stress from one hand and to maintain 
the immunosuppressive microenvironment, from the other hand, 
ultimately promoting disease progression and drug resistance. 
However, loss of ER proteostasis along with other housekeeping 
mechanisms may enable key chaperones like CRT and HSP70, 
with extracellular immunomodulatory functions, to get exposed 
on the surface of the dying melanoma cells, and modulate antitu-
mor immunity in response to certain anti-melanoma therapies. 
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These observations highlight the plasticity and context-dependent 
relevance of proteostasis control in melanoma.
DegRADe AND ReCYCLe: AuTOPHAgY 
“ON DeMAND” iN MeLANOMA
Several recent studies have highlighted that the transition from 
the melanocytes to malignant melanoma cells entails changes 
in major degradation pathways (121–126). Recent studies have 
shown that the role of autophagy (Box  2) in carcinogenesis is 
highly context dependent. On the one hand, it may act as a tumor 
suppressor by removing damaged and ROS-producing organelles, 
primarily mitochondria thereby favoring metabolic homeostasis 
and counteracting metabolic rewiring characteristic of malignant 
cells (122–124, 127). Moreover, autophagy has been proposed to 
prevent malignancy by decreasing the risk of genome instability, 
favoring oncogene-induced senescence, degrading oncogenic 
proteins, ensuring the maintenance of normal stem cell popula-
tions, lowering inflammation, and regulating immune responses 
(123). On the other hand, in established tumors, autophagy may 
favor oncogenesis by providing tumor cells with essential amino 
acids or an alternative energy supply to boost their metabolic 
need under conditions of nutrient and oxygen deprivation, a 
typical phenomenon of the tumor environment (66). Moreover, 
in the tumor microenvironment, cancer cell-associated and stro-
mal cell-associated autophagy engage in a tight cross talk that 
favors cancer cell dissemination through the blood stream (127, 
128), repression of antitumor immunity (127), and exchange 
of metabolites supporting cancer cell’s metabolic needs (129). 
Therefore in established tumors, in many instances, albeit not in 
all, blocking autophagy results in increased therapeutic efficacy 
[reviewed in Ref. (127)].
Although evidence reporting autophagy alterations during 
melanoma progression is still incomplete, available knowledge 
supports a dynamic implementation of autophagy in melanom-
agenesis and melanoma dissemination. In the early phases of 
melanoma growth, mRNA and protein expression levels of the 
pro-autophagic proteins Beclin 1 and LC3 have been found to 
be lower compared to benign nevi (130). Primary melanoma 
cells also display reduced expression levels of ATG5, a factor 
which was associated with a worse prognosis (131). Induction 
of autophagy by ectopic ATG5 expression or autophagy inducers 
attenuated clonogenic growth of melanoma cell lines harboring 
low ATG5 levels (131). Downregulation of ATG5 promoted 
melanocytes transformation by curtailing oncogene-induced 
senescence (131). Moreover, the use of the lysosomotropic drug 
chloroquine (CQ) revealed that primary melanoma cells have a 
reduced autophagic flux in comparison with melanocytes (132).
Collectively, these studies support the hypothesis that 
early during melanomagenesis the tumor-suppressive role of 
autophagy is repressed (132). This phenomenon appears to be 
regulated by epigenetic mechanisms (133) and, at least in part, 
by the autophagy-inhibitory activity exerted by the heightened 
activity of the AKT pathway in primary melanoma (132).
Efficient autophagic capacity is recovered during melanoma 
progression along with the acquisition of other mutations altering 
the oncogenic landscape. In line with this, metastatic melanoma 
cells have a higher autophagic flux in comparison to primary 
melanoma and melanocytes, which was found to be a crucial 
transition for their survival and clonogenic expansion (132). This 
switch toward a restoration in the autophagy capacity associated 
to the invasive/aggressive melanoma phenotype is further sup-
ported by analysis of biopsies from human melanoma patients. 
Consistently higher LC3B and Beclin 1 expression are found in 
samples of patients with advanced/metastatic melanoma as com-
pared to non-invasive, primary tumors (134–136). Furthermore, 
increased levels of autophagy prior to treatment in metastatic 
melanoma have been shown to predict invasiveness, chemoresist-
ance, and poor patient survival (135).
These data support the concept that autophagy in melanoma 
is regulated in a somewhat biphasic manner. Early in melanom-
agenesis autophagic flux is decreased, a condition that may favor 
accumulation of pro-oncogenic mutations and cellular damage, 
ultimately supporting malignant transformation. In the later 
stages of melanoma progression autophagy is reactivated, to 
serve as a major pro-survival mechanism supporting the high 
metabolic demands and adaptation to stressful tumor microen-
vironment conditions (118, 132, 136). In line with this, studies 
using a melanoma xenograft model showed that compromising 
melanoma cell-associated autophagy by silencing ATG1 or 
VPS34 (class III PI3K) expression, increased melanoma cell 
death induced by leucine deprivation (137). Moreover, in a 
syngeneic host, murine B16F10 melanoma cells silenced for 
the expression of ATG5 exhibited a severely reduced growth 
potential, inability to survive in the blood stream and metas-
tasize (128), thus indicating a general role of pro-autophagic 
proteins in supporting metastatic melanoma dissemination. 
Likewise, Beclin 1 silencing in B16F10 melanoma halted tumor 
growth and increased apoptosis in vivo (138) [further reviewed 
in Ref. (139)].
Interestingly, the expression of the HIF1-responsive gene 
BCL-2/adenovirus E1B 19  kDa protein-interacting protein 3 
(BNIP3), an atypical BH3-only protein contextually implicated 
in the regulation of both cell death and autophagy (140), is consti-
tutively higher in melanoma cells as compared to normal melano-
cytes (141). BNIP3 via its BH3 domain can displace Beclin 1 from 
its interaction with Bcl-2, therefore activating autophagy, while 
through its LIR motif, functions as an autophagy receptor for the 
clearance of mitochondria (142). In melanoma cells, BNIP3 not 
only regulates autophagic clearance of ROS-generating mitochon-
dria but is also a key orchestrator of actin-driven formation of PM 
protrusions (ruffles), melanoma cell morphology, and migration 
(141). Intriguingly, melanoma cell-associated BNIP3 was also 
found to regulate the stability of the integrin-associated CD47 a 
surface molecule acting as a powerful “don’t eat me signal” that 
favors cancer cell escape from immunosurveillance mechanisms 
during carcinogenesis, a property that is not shared with ATG5 
(141). This suggests that BNIP3 is an essential player in the regu-
lation of melanoma cell proteostasis, a function that is exerted 
by the dual regulation of the pool of healthy mitochondria, with 
crucial implications for melanoma bioenergetics and metabolic 
reprograming, and the composition of the PM, possibly affecting 
melanoma’s phagocytic barrier. In line with this, co-regulated 
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BNIP3/CD47 mRNA expression is correlated to cancer progres-
sion and poor prognosis (141).
In line with a tumor-promoting role of autophagic pathways in 
advanced melanoma, several studies have shown that pharmaco-
logical or genetic inhibition of autophagy increase drug-induced 
cytotoxicity in melanoma cells (127). With the intensive interest 
of targeted therapy, great relief came with the initial clinical suc-
cess of BRAF inhibitors (BRAFi), targeting the V600E mutation 
in melanoma such as vemurafenib (or PLX4032). Unfortunately, 
the development of drug resistance and relapse prevailed within 
1 year of therapy initiation (143). Although a significant number 
of studies have highlighted the rationale for the inevitable acquisi-
tion of drug resistance in melanoma, the underlying mechanisms 
still remain largely unsolved (144).
Recently it was reported that patients harboring BRAFi/
vemurafenib-resistant melanoma’s displayed heightened levels 
of autophagy compared with their responsive counterparts, and 
those patients displaying increased levels of therapy-induced 
autophagy had drastically lower response rates to BRAFi and 
poor prognosis (145). Interestingly, the CQ derivative Lys05 
potentiated BRAFi-induced cell death and enhanced its anti-
tumor activity in mice bearing MEL624 melanoma xenografts 
(145), suggesting that targeting the heightened lysosomal path-
way displayed by these drug-resistant melanoma cells may be of 
therapeutic benefit. At the mechanistic level, BRAF inhibition 
in BRAFV600E-melanoma cells induced ER-stress and the pre-
dominant activation of the PERK–eIF2α–ATF4/ATF3 pathway, 
which in turn promoted cytoprotective autophagy (145). Notably, 
inhibition of mutant BRAFV600E by vemurafenib increased its 
interaction with both the ER-associated and cytosolic pools of 
GRP78, thereby ensuing the ER-stress response (145). Thus, 
deregulated MAPK signaling in melanoma cells alters chaperone-
mediated quality control mechanisms, which in turn triggers 
protective proteostatic measures, through the cross talk between 
UPRER and autophagy. Together, these stress responses alleviate 
sufficient proteotoxic stress to allow melanoma cells to adapt and 
evolve molecular mechanisms that circumvent BRAF inhibi-
tion and reactivate MEK-based signaling, ultimately leading to 
increased resistance to proteotoxic stress (145). Altogether, these 
findings suggest that targeting melanomas’ addiction to autophagy 
in late stage metastatic disease could compromise vital cellular 
mechanisms of protection against proteotoxic stress. In line with 
this, suppression of autophagy has been shown to exacerbate 
amyloidogenic-stress caused by persistence of aggregate-prone 
or amyloid-like proteins in other paradigms (146, 147).
However, contrary to several reports indicating a cytoprotec-
tive role of autophagy in anti-melanoma therapy, other studies 
have also reported that the autophagy machinery could favor or 
promote proteotoxic stress and melanoma killing. For example, 
an autophagy-dependent, caspase-independent melanoma cell 
death mediated by ROS generated by the photoactivation of 
5-ALA has been shown to dependent on the melanin content, 
such that only non-pigmented melanoma cells died through 
autophagy (148). Melanoma killing, both in  vitro and in  vivo, 
in response to the dsRNA mimic, PEI-conjugated polyinosine–
polycytidylic acid (pIC), was found to be mediated by the ability 
of the dsRNA helicase melanoma-differentiation-associated 
gene 5 (MDA-5) to drive endosome–autophagosome–lysosome 
fusion events, ultimately leading to NOXA-induced apoptosis 
(149). These studies suggest that conditions altering the cross talk 
among proteostatic pathways, or exacerbating fusion events in the 
endo-lysosomal pathway, may turn off the intrinsic pro-survival 
function of certain autophagy mediators, thereby amplifying the 
activation of cell death pathways.
Moreover, it should be also considered that autophagy-
independent processes are emerging for autophagy-related genes. 
Of note, melanin biogenesis [a process known to require some 
components of the autophagy machinery like WIPI1 (150)] has 
been recently shown to be negatively regulated by ULK1, inde-
pendent of its canonical autophagy-inducing role through the 
ATG13/FIP200 complex and mTORC1 regulation (151). ULK1 
depletion increased the levels of melanin and was implicated in 
MITF-mediated induction of tyrosinase (TYR), the rate-limiting 
factor in melanin biogenesis (151). Whether ULK1 acquires 
pro-death properties and mediates ROS-induced cell death in 
non-pigmented melanoma cells remains to be investigated.
Finally, also the in  vivo autophagy-independent effects of 
the first-generation autophagy inhibitors, CQ/hydroxychloro-
quine (HCQ), should be considered, as recently evidenced in 
a melanoma mouse model where the key autophagy gene Atg5 
was deleted either in melanoma cells or in the tumor vasculature 
(128). We found that in vivo CQ reduced intratumoural hypoxia 
and metastasis, while improving chemotherapy response, largely 
by eliciting tumor vessel normalization. This CQ-mediated 
effect was independent on endothelial cell-associated ATG5 but 
involved alterations in the trafficking and degradation mecha-
nisms of the antiangiogenic NOTCH1 receptor, resulting in its 
activation through the endocytic route (128).
In addition, as mentioned above, autophagosomes can 
interact/interplay at multiple stages of the endocytic pathway, 
a vital process that is ruthlessly exploited by melanoma cells to 
support progression and malignancy (125, 152), thus allowing 
for additional cross talk between trafficking and degradation 
mechanisms regulating melanoma proteostasis.
In conlusion, in spite of the emerging evidence indicating that 
autophagy plays a pivotal role in melanoma, a better understand-
ing of the complex and context-dependent relationship that 
exists between the (epi)genetic profile of the evolving melanoma 
cell and its interaction with key microenvironmental factors is 
required to devise therapeutic strategies aiming at harnessing 
autophagy in melanoma.
ON THe MOve: eNDO/LYSOSOMAL 
SigNALLiNg iN MeLANOMA
Although aberrations in vesicular trafficking pathways (Box 3) 
may not be themselves the drivers of tumorigenesis, they may be 
utilized by cancer cells, on “demand,” to support oncogene-driven 
proliferation, to facilitate invasion and seeding to other organs, 
and to increase the plasticity of the interface with other stromal 
cells (153). Moreover, deranged vesicular trafficking may alter the 
accurate recycling, delivery, and degradation of proteins, result-
ing in a new compendium of surface localized proteins and lipids 
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that may alter signaling circuits, adhesion/migratory properties, 
and invasion mechanisms, favoring cancer progression (153). In 
line with this, accumulating evidence indicates that vesicle traf-
ficking and lysosomal degradative pathways modulate melanoma 
plasticity and favor dissemination (125, 127, 154).
Gene expression profiling and experimental evidence indicate 
that during melanomagenesis, high levels of MITF in melanoma 
cells are associated with a vesicular trafficking signature hall-
marked by high expression of Rab7, TBCD1D16, and Rab27a 
(155). Moreover, as discussed above, MITF-driven ELS biogen-
esis results in stimulation of Wnt signaling from the MVBs (120), 
which in turn support melanoma proliferation. The expression 
levels of MITF, encoding a basic helix–loop–helix/leucine zipper 
transcription factor, which is found mutated (156) or amplified 
in 30–40% of melanoma’s (157), is dynamically altered during 
melanoma progression depending on the need. In general, a large 
body of evidence supports the view that increasing levels of MITF 
expression promote melanoma proliferation and drug resistance 
(126) [extensively reviewed in Ref. (158)]. However, a recent study 
also reported that decreased/loss of MITF expression in conjunc-
tion with an increased expression/activation of receptor tyrosine 
kinases (RTKs), like AXL and EGFR in melanoma cells correlated 
with increased cross-resistance toward MAPK pathway inhibitors 
and the induction of an invasive melanoma phenotype, suggest-
ing that the oncogenic role of MITF is modulated by its cross 
talk with RTK pathways (159). Moreover, whether this is linked 
with MITF-driven alterations in the ELS affecting recycling and 
signaling properties of melanoma-associated RTKs (160) has not 
been explored yet.
Microphthalmia-associated transcription factor is a member of 
the MiT family of transcription factors, which include transcription 
factor EB (TFEB), the master regulator of lysosome biogenesis and 
autophagosomes formation, through the regulation of the expres-
sion of genes belonging to the coordinated lysosomal expression 
and regulation (CLEAR) network (161) in an mTOR-dependent 
manner (162). TFEB has also been reported to be a target of ERK2 
and starvation along with ERK2 inhibition promoted TFEB nuclear 
translocation and consequent stimulation of the autophagic/lyso-
somal program (161). Although the role for TFEB in melanoma is 
still understudied, it would be interesting to investigate if blockage 
of this MAPK–TFEB pathway in combination with leucine starva-
tion is a way to keep autophagy at bay and elicit caspase-dependent 
apoptotic cell death of melanoma cells (137).
Within the endo-/lysosomal gene cluster identified in mela-
noma, Rab7 was recently found to be differentially expressed in 
melanoma cells, compared to normal melanocytes and other 
non-melanocytic tumor cell lines, and to foster melanoma 
growth by accelerating migration/invasion dynamics (125). 
Moreover, promoter-based analysis identified the neural crest 
lineage master regulator SOX10 and the oncogene MYC as driv-
ers of Rab7 transcription in melanoma (125). Increased expres-
sion of Rab7A in human cells, clinical specimens, and mouse 
models highlighted that this key membrane traffic regulator is 
an early-induced melanoma driver, to which melanoma become 
particularly addicted to support their increased invasiveness and 
metastatic potential (125).
Moreover, a heightened “endo-/lysosomal status” could favor 
melanoma plasticity, by facilitating the uptake of key nutrients 
from the extracellular environment required to sustain mela-
noma cell’s high proliferation rates (163). In line with this, Class 
I PI3K signaling has been shown to promote macropinocytosis 
upon oncogene activation in human melanocytes and to recruit 
Rab7A for their degradation (164). Interestingly, Golgi phos-
phoprotein 3 (GOLPH3), a Golgi-localizing protein, is encoded 
by 5p13, a region that is focally amplified in melanoma (165). 
GOLPH3 is important in endosomal-trans golgi signaling and 
has been shown to enhance endocytosis in melanoma cells via 
interaction with VPS35. Furthermore, expression of GOLPH3 
increased mTOR and AKT activity, whereby in melanocytes 
GOLPH3 overexpression in conjunction with mutant BRAF or 
NRAS resulted in increased anchorage-independent and xeno-
graft growth in vivo (165).
This heightened endo-lysosomal signature in the early phase 
of melanomagenesis could be hijacked to plastically support 
the melanoma phenotype switching paradigm. Melanoma phe-
notype switching, also referred to as EMT-like transition, is a 
hallmark of the plastic nature of this cancer. EMT-like transition 
entails that a reversible expression of a set of genes regulating 
either a “proliferative signature” or an “invasive signature,” 
is imposed by key microenvironmental factors (i.e., hypoxia, 
inflammation) rather than the acquisition and selection of 
specific pro-metastatic mutations and is reversibly acquired “on 
demand” to support melanoma escape and proliferation at a 
new metastatic site. In line with this, melanoma subpopulations 
have been shown to harbor specific gene expression programs, 
whereby “proliferative” melanoma cells display MITFhigh, 
SOX10high, and PAX3high, in line with the reported function of 
MITF in driving endosomal biosynthesis and Wnt-mediated 
proliferation. On the other hand, invasive cells have a MITFlow, 
TGF-signalinghigh, ZEB1high signature (166). Moreover, the 
strength but also the duration of TGF-β signaling, which is 
hyperactivated in the invasive melanoma cells, is highly affected 
by the internalization route and the capacity to signal from the 
endosomes (167). Additionally, E-cadherin a junction protein, 
present in the proliferative melanoma cells is not only regu-
lated by genetics and epigenetics but also by endocytosis and 
endosomal recycling. Indeed, EMT-inducing stimuli promote 
E-cadherin ubiquitination and subsequent lysosomal degrada-
tion in a process that requires the sequential activation of Rab5 
and Rab7 (168). Altogether, these data support the idea that the 
dynamics of the endocytic compartment play an important role 
in the plastic phenotype switching of the melanoma cells.
Taken together, these studies suggest that although the 
ELS is not a direct driver of melanoma progression, enhanced 
lysosomal functionality is a key weapon within the melanoma’s 
arsenal. Moreover, exacerbated ELS may indirectly drive dis-
ease progression by accelerating and facilitating invasion or 
metastasis and by buffering the enhanced proteostatic burden 
or by supplying additional materials required for melanoma 
growth, spread, and progression. Finally, its role in shaping 
the extracellular matrix may also aid in or promote melanoma 
plasticity.
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COMMuNiCATe AND eDuCATe: 
MeLANOMA-DeRiveD exOSOMeS
Melanoma cells not only rewire intracellular adaptations and 
degradative pathways to their advantage but also upregulate 
intercellular communication pathways that enable them to sup-
port neighboring melanoma cells and educate the tumor stroma 
and prime (pre)metastatic sites for subsequent invasion (39, 169). 
An intercellular messenger system key for melanoma progression 
and metastasis are the secreted vesicles. Melanoma cells secrete 
multiple extracellular vesicles, which are highly heterogenic 
in their origin, composition, and size. The best characterized 
secreted extracellular vesicles are the exosomes, which are formed 
in the cell cytoplasm within the multivesicular bodies, trafficked 
to the cell borders via the cytoskeleton and subsequently released 
upon fusion with the PM. With their small diameters of less than 
150 nm, exosomes function as tiny messenger bags, which not 
only contain proteins but also lipids, DNA, and RNAs. On top 
of a specific cargo, these messenger bags also contain a specific 
delivery address, which is indicated by the composition of the 
membrane, including specific integrin expression patterns, which 
target them to a specific cell subtype (170). Upon delivery of the 
exosomes to the target cell, the intracellular signaling can be 
altered either by direct activation of PM receptors or via fusion 
of the exosome with the PM and subsequent release of its content 
in the cytosol of the target cell (171). The formation, trafficking, 
secretion, and uptake of exosomes is regulated at multiple steps by 
several signaling molecules, including the Rab family of proteins 
(172, 173).
As mentioned above, melanoma cells have been found to 
express high levels of key regulators of exosomes formation 
and trafficking pathways (102), indicating their propensity 
to recruit the ELS to communicate with their environment. 
The first functional evidence for a tumor-supportive role for 
melanoma-derived exosomes was already produced a decade 
ago when it was shown that the metastatic potential of the 
aggressive BL6-F10 melanoma cell lines could be transferred 
to the poorly metastatic BL6-F1 melanoma cell line via the 
exosomes (169). More recently, exosomes secreted by mela-
noma cell lines have been shown to induce EMT-like transition 
in normal melanocytes (39). The relevance of exosomes for 
autocrine/paracrine signaling is also supported by findings 
showing that exosomes secreted by miRNA22-overexpressing 
melanoma cells are capable to transfer the miRNA 22-depend-
ent malignant potential of the overexpressing cells to the 
wild-type cells (40). Besides affecting neighboring melanocytes 
and melanoma cells, melanoma-secreted exosomes have been 
reported to have profound paracrine effects on the tumor 
stroma. One of the tumor stroma components reported to be 
activated by melanoma-derived exosomes are the endothelial 
cells of the tumor vasculature. Several reports show the presence 
of multiple proangiogenic molecules, including IL-6, MMP2, 
and VEGFA, in melanoma-derived exosomes (41, 45, 102, 
174). Another tumor stroma component whose functionality 
is altered/modulated by the tumor-secreted exosomes are the 
immune cells. Melanoma-derived exosomes have been shown 
to prevent monocytes differentiation into dendritic cells and 
instead skew them toward TGF-β secreting myeloid cells, 
capable of suppressing T-cell activation and proliferation (175, 
176). Moreover MHC class II-containing exosomes isolated 
from the plasma of melanoma bearing mice have been shown 
to suppress the tumor antigen-induced immune response in 
an ovalbumin–antigen model (177). It has been proposed that 
melanoma-derived exosomes could also induce immune toler-
ance in the draining lymph nodes by increasing the production 
of TNF-α by vascular endothelial cells (42).
A unique signaling feature of exosomes is their long half-life 
in the blood, which makes them excellent long distance mes-
sengers for the tumor-induced priming of the (pre)metastatic 
niche. An elegant study by the group of D. Lyden revealed that 
melanoma-derived exosomes educate bone marrow-derived cells 
toward a tumor-promoting phenotype supporting angiogenesis, 
metastasis, and invasion, by increasing their MET signaling 
(102). The importance of exosomes in the establishment of the 
(pre)metastatic niche is also supported by studies showing that 
melanoma-derived exosomes uptake in the sentinel lymph node 
increases melanoma cell recruitment, extracellular matrix depo-
sition, and blood vessel activation (45).
Recent patient sample analysis has documented an increase in 
exosome number and size distribution (44), or higher exosome 
protein concentrations and a different composition, in patients 
with advanced disease compared to all other stages (102). In 
particular, exosomes of melanoma patients were shown to display 
higher protein levels of melanoma inhibitory activity (MIA), a 
small soluble protein of 11 kDa secreted by malignant melanoma 
cells, and S100B, a 21-kDa dimeric calcium-binding protein 
biomarker for malignant melanoma, known to contribute to 
melanoma progression at metastatic niche (46, 178). This tight 
correlation between exosomal protein content and melanoma 
progression was further confirmed in an in  vitro study where 
exosomes from metastatic melanoma cell lines were shown to 
have a specific protein signature (102, 174).
As mentioned before, certain vital components of the pro-
teostasis system, such as HSP70, are expressed within the endo-
lysosomal compartment and at the PM and can be secreted on the 
membrane of exosomes. A recent study has shown that a peptide 
aptamer targeting the extracellular domain of HSP70 disrupts the 
interaction between exosome-associated HSP70 and the toll-like 
receptor (TLR) 2 on myeloid-derived suppressor cells (MDSCs), 
potent suppressors of antitumor immunity, thereby lowering 
their proliferation (47). This effect was particularly evident 
after cisplatin or 5FU treatment, thus suggesting that blocking 
the exosomal source of HSP70 may improve the efficacy of 
anticancer drugs by blunting the immune suppressive functions 
of melanoma-associated exosomes. This hypothesis still needs to 
be further proven and evaluated in the context of clinically used 
anti-melanoma therapies.
Although the true implications of exosome-based communi-
cation (both between cancer cells and neighboring cells) is still 
being unraveled, the studies discussed above highlight a vital 
role for melanoma-derived exosomes in facilitating and sup-
porting multiple steps of melanoma progression. In that context, 
melanoma-derived exosomes may hold value as diagnostic and 
prognostic biomarkers of disease progression.
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CONCLuSiON AND PeRSPeCTiveS
Research over the past decades has evidenced the ability of 
melanoma cells to hijack various homeostatic processes to adapt 
to the changing and hostile microenvironment and disseminate. 
One of the most successful strategy adopted by melanoma cells to 
foster their plasticity is to model regulatory pathways governing 
proteostasis. This is achieved by the recruitment of a cluster of 
lysosome- and endolysosome-associated genes, by expanding and 
modulating the unfolded protein and the HSRs and autophagy/
degradative pathways, and by intensifying or even generating 
novel and robust communication routes within the main nodes of 
the proteostasis network (schematically illustrated in Figure 1). 
Perturbing degradation, recycling and trafficking mechanisms 
alter the functional status of signaling proteins/receptors within 
the endo-lysosomal network or movement of endocytic cargo 
to inappropriate destinations (e.g., shifting the cargo from 
degradation to recycling or secretion). Ultimately, this deranged 
proteostasis network is reflected in changes of melanoma cell’s 
proteome and secretome, which plastically fuel melanoma 
aggressive behavior and shape the microenvironment. However, 
such a dependency also reveals an intrinsic vulnerability of mela-
noma cells, which can be exploited therapeutically. For example, 
autophagy pathways at the late stage of melanoma development, 
when they become exquisitely important for melanoma survival 
and growth, can be therapeutically targeted. Understanding how 
and when sabotage of the altered proteostasis system in melanoma 
can be harnessed for therapeutic purposes is an outstanding ques-
tion that will require future studies. Future studies would need 
to identify the high connectivity points within a network that 
are more susceptible to lethal perturbations. Research is already 
progressing in that direction as demonstrated by recent studies 
that show the increased therapeutic benefit of combining inhibi-
tors of multiple deranged proteostasis pathways. In this context, it 
would be interesting to model proteostasis network of melanoma 
cell at the system level, in order to model the deranged nodes and 
predict lethal perturbations. Finally, these system biology and 
therapeutic approaches would need to be tested and/or translated 
in vivo to understand the impact of the induced melanoma cell 
proteotoxicity, at the tumor microenvironmental level.
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